Indus Gene Expressions Limited

Indus Gene Expressions Limited - life sciences in Andhra Pradesh, India. FY 2026 financials & compliance.
CIN U24231AP2007PLC113311 Incorporated 09 February 2007 ROC Vijayawada HQ Andhra Pradesh, India
Active Public Limited Company life sciences
Data last updated
Revenue · FY 2023
₹16.82 Cr
▲ 570% YoY
Net profit · FY 2023
₹10.28 Lakh
Net margin 0.6%
EBITDA · FY 2023
₹11.71 Cr
EBITDA margin 69.6%
Authorised capital
₹100 Cr
Registered with MCA
Paid-up capital
₹92.83 Cr
Issued & subscribed
Open charges
₹32.63 Cr
Satisfied ₹30.4 Cr
Company age
19 yrs
Est. 2007
Employees · EPFO
29
Provident fund records

About Indus Gene Expressions Limited

Data last updated:

Indus Gene Expressions Limited is a public limited company based in Andhra Pradesh, India. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 09 February 2007 and has been in existence for over 19 years.

The company is registered with the Registrar of Companies (ROC), Vijayawada, under CIN U24231AP2007PLC113311. Its GSTIN is 37AABCI9124R1ZY (Andhra Pradesh).

The company has an authorised share capital of ₹100 Cr and a paid-up capital of ₹92.83 Cr. It was formerly known as Indus Gene Expressions Private Limited and Sri Balaji Biopharmaceuticals India Private Limited. It is led by directors including Channa Reddy C and Meka Sudhakara Reddy.

Its last annual general meeting (AGM) was held on 30 September 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office is at 6 – 312 Kodur Village Kanisettipalli Post, Andhra Pradesh, India – 515341.

As per the financials filed for FY 2023, the company reported a revenue of ₹16.82 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹10.28 Lakh (net margin 0.6%) and EBITDA of ₹11.71 Cr (EBITDA margin 69.6%). Revenue has grown at a compounded annual rate (CAGR) of 639% over five years.

The company has about 29 employees on its provident fund (EPFO) records.

As per MCA filings, the company has open charges of ₹32.63 Cr and satisfied charges of ₹30.4 Cr on record. Court records list 10 cases involving the company, including 9 filed by the company and 1 filed against it; 3 cases are pending. The company has 24 deals on record (18 secondary share transfers, 6 funding rounds), with disclosed funding of ₹63.95 Cr; the latest was in May 2022. Its 10 peer companies in the Biotechnology industry (Biotechnology) are compared by revenue, 5 larger and 5 smaller; the largest is Cellutions Biostorage Private Limited with revenue of ₹17.29 Cr. The company has 2 MSME Form 1 returns on record for the period ending Sep 2019, listing 17 overdue payments to 9 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website indusgenetech.com.

Company Details of Indus Gene Expressions Limited
CIN U24231AP2007PLC113311
Registration Number 113311
Incorporation Date 09 February 2007
ROC Vijayawada
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2023
Date of Balance Sheet 31 March 2023
Compliance Status Active Compliant
Key People
Usharani Reddy C Cfo Channa Reddy C Director Meka Sudhakara Reddy Additional Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    indusgenetech.com
  • Social Media
    Locked
  • Registered Address
    6 – 312 Kodur Village Kanisettipalli Post, Andhra Pradesh, India – 515341
  • Industry
    Life Sciences, Biotechnology
Comprehensive company report
Indus Gene Expressions Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Indus Gene Expressions Limited report

Financials, compliance, directors, charges, ownership and filings for Indus Gene Expressions Limited in one report.

Financials from 2015 Directors & ownership Charges & compliance

Financials of Indus Gene Expressions Limited FY 2023 filings available

Indus Gene Expressions Limited reported revenue of ₹16.82 Cr (up 570% YoY) for FY 2023.

Revenue · FY 2023
₹16.82 Cr ▲ 570%
Net profit · FY 2023
₹10.28 Lakh margin 0.6%
EBITDA · FY 2023
₹11.71 Cr margin 69.6%

Compounded Annual Growth Rate (CAGR) of Indus Gene Expressions Limited

Revenue CAGR growth
1 year
▲ 570%
5 years · compounded
▲ 639%
EBITDA CAGR growth
3 years · compounded
▲ 519%
5 years · compounded
▲ 356%

Revenue has grown at a compounded annual rate (CAGR) of 639% over five years, including 570% growth in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary of Indus Gene Expressions Limited

MetricsFY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Profit and Loss Statement
Revenue from Operations••••••••••••••••••••
Other Income••••••••••••••••••••
Total Revenue₹16.82 Cr••••••••••••••••
Cost of Materials Consumed••••••••••••••••••••
Employee Benefit Expense••••••••••••••••••••
Finance Costs••••••••••••••••••••
Depreciation and Amortisation••••••••••••••••••••
Other Expenses••••••••••••••••••••
Total Expenses••••••••••••••••••••
EBITDA₹11.71 Cr••••••••••••••••
Profit Before Tax••••••••••••••••••••
Tax Expense••••••••••••••••••••
Net Profit (PAT)₹10.28 Lakh••••••••••••••••
Balance Sheet
Share Capital••••••••••••••••••••
Reserves and Surplus••••••••••••••••••••
Net Worth (Total Equity)••••••••••••••••••••
Long-term Borrowings••••••••••••••••••••
Short-term Borrowings••••••••••••••••••••
Trade Payables••••••••••••••••••••
Total Liabilities••••••••••••••••••••
Fixed Assets••••••••••••••••••••
Investments••••••••••••••••••••
Inventories••••••••••••••••••••
Trade Receivables••••••••••••••••••••
Cash and Bank Balance••••••••••••••••••••
Total Assets••••••••••••••••••••

Financial Ratios of Indus Gene Expressions Limited

MetricsFY 2022-23FY 2021-22FY 2020-21FY 2019-20FY 2018-19
Profitability
EBITDA Margin69.6%••••••••••••••••
Net Profit Margin0.6%••••••••••••••••
Return on Equity (ROE)••••••••••••••••••••
Return on Capital Employed (ROCE)••••••••••••••••••••
Return on Assets (ROA)••••••••••••••••••••
Liquidity and Debt
Current Ratio••••••••••••••••••••
Quick Ratio••••••••••••••••••••
Debt-to-Equity Ratio••••••••••••••••••••
Interest Coverage Ratio••••••••••••••••••••
Efficiency and Growth
Asset Turnover••••••••••••••••••••
Receivable Days••••••••••••••••••••
Payable Days••••••••••••••••••••
Inventory Days••••••••••••••••••••
Revenue Growth••••••••••••••••••••
Net Profit Growth••••••••••••••••••••

Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Indus Gene Expressions are in the company report.

Premium access

Financial statements from 2015

Earlier years and trend charts are in the company report.

  • Income statements
  • Balance sheets
  • Cash-flow statements
  • Ratios and benchmarks

Verified entity values are shown only after access is granted.

Peer Comparison of Indus Gene Expressions Limited

Indus Gene Expressions Limited is compared with the companies closest to it by revenue in the Biotechnology industry (Biotechnology). Net profit, margin and employee counts of each company are in the company report.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Cellutions Biostorage Private Limited₹17.29 Cr (FY 2025)••••••••1.0%••••Kanchipuram, Tamil Nadu, India
S4 Research Private Limited₹17.22 Cr (FY 2024)••••••••3.0%••••Ahmedabad, Gujarat, India
Juniper Life Sciences Private Limited₹17.18 Cr (FY 2024)••••••••23.0%••••Bengaluru, Karnataka, India
Gangabishan Bhikulal Investment and Trading Limited₹16.96 Cr (FY 2023)••••••••20055.0%••••Mumbai, Maharashtra, India
Micro Bax (India) Limited₹16.94 Cr (FY 2020)••••••••-1.0%••••Hyderabad, Telangana, India
Indus Gene Expressions Limited this company₹16.82 Cr (FY 2023)••••••••570.0%••••Andhra Pradesh, India
Dhiti Life Sciences Private Limited₹16.67 Cr (FY 2025)••••••••54.0%••••New Delhi, Delhi, India
Provis Biolabs Private Limited₹16.57 Cr (FY 2025)••••••••-1.0%••••Hyderabad, Telangana, India
Acrannolife Genomics Private Limited₹16.55 Cr (FY 2024)••••••••108.0%••••Chennai, Tamil Nadu, India
String Bio Private Limited₹16.49 Cr (FY 2024)••••••••16.0%••••Yeshwanthpur Hobli Bangalore, Karnataka, India
Life Technologies (India) Private Limited₹16.27 Cr (FY 2025)••••••••-16.0%••••Delhi, India

Peers are the five companies nearest above and the five nearest below Indus Gene Expressions by revenue in the Biotechnology industry (Biotechnology), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.

Auditor Details of Indus Gene Expressions Limited

Auditor information for Indus Gene Expressions Limited provides details about the firm responsible for auditing the company's financial statements and ensuring compliance with regulatory requirements.

Board of Directors and KMP of Indus Gene Expressions Limited

Indus Gene Expressions Limited currently reports 5 directors and 1 key managerial person. 16 former directors have served the organization.

Current Directors and KMP
NameDesignationAppointment DateTenureStatus
Usharani Reddy C
Also directs: Dr.Reddy Solar Energy and Systems Private Limited
Cfo03 Apr 20197 Years 6 MonthsCurrent
Channa Reddy C
Also directs: Pennzymes International Private Limited, Dr.Reddy Solar Energy and Systems Private Limited
Director06 Nov 200817 Years 11 MonthsCurrent
Meka Sudhakara ReddyAdditional Director06 May 20224 Years 5 MonthsCurrent
Avula Sreenivasa ReddyAdditional Director28 Oct 20196 Years 11 MonthsCurrent
Muktha Puram KrishnaAdditional Director28 Sep 20242 Years 0 MonthsCurrent
Abhinaya Chinthamani ReddyAdditional Director15 Jan 20251 Years 8 MonthsCurrent
View all directors and KMP

Ownership and Shareholding of Indus Gene Expressions Limited

Premium access

Shareholding and ownership data

Promoter, institutional, public and beneficial ownership figures are in the company report.

  • Ownership categories
  • Historical changes
  • Group structure
  • FII and DII holdings

Verified entity values are shown only after access is granted.

Charges & Borrowings of Indus Gene Expressions Limited

Open charges
₹32.63 Cr
Satisfied charges
₹30.4 Cr
Breakdown by lending institutions
Syndicate Bank₹29.00 Cr
Canara Bank₹3.63 Cr
Latest charge details
DateLenderAmountStatus
04 Sep 2020Canara Bank₹3.63 CrOpen
21 Dec 2019Syndicate Bank₹29 CrOpen
13 Oct 2014Andhra Bank₹30.4 CrSatisfied

Total charge records: 3 View all charges

Deals & Funding of Indus Gene Expressions Limited

Indus Gene Expressions Limited has 24 deals on record (18 secondary share transfers, 6 funding rounds), with disclosed funding of ₹63.95 Cr; the latest was in May 2022.

Total deals
24
Secondary share transfers
18
Funding rounds
6
Disclosed funding
₹63.95 Cr

Deals on record (5 of 24)

WhenDealAmountParties
May 2022Funding round₹2.06 CrInvestors: an individual
Jul 2021Secondary share transferUndisclosedBuyer: an individual
Seller: an individual
Jul 2021Funding round₹12.8 CrInvestors: an individual
Mar 2021Secondary share transferUndisclosedBuyer: 2 individuals
Seller: an individual
Mar 2021Secondary share transferUndisclosedBuyer: Tri Solar Private Limited
Seller: an individual
Premium access

Full deal history

All 24 deals with amounts, valuations, instruments and every party are in the company report.

  • Every funding round and share transfer
  • Amounts and valuations
  • Investors, buyers and sellers
  • Instruments and deal dates

Verified entity values are shown only after access is granted.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME Payment Delays by Indus Gene Expressions Limited

Indus Gene Expressions Limited has 2 MSME Form 1 returns on record for the period ending Sep 2019, listing 17 overdue payments to 9 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 9)

SupplierAmount dueDue sinceReported on
Kala G Granite••••••••••••
Elite Associates••••••••••••
Sunlight Gas & Equipments Private Limited••••••••••••
Shivani Interior Solutions Private Limited••••••••••••
C4g Automation Private Limited••••••••••••
Premium access

Full MSME payment history

Every supplier, amount and due date from all 2 MSME Form 1 returns is in the company report.

  • Every reported supplier due
  • Amounts and due dates
  • Reasons given in each return
  • Period-by-period history

Verified entity values are shown only after access is granted.

Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.

Employees and EPFO Compliance at Indus Gene Expressions Limited

Employment history and EPFO contributions of people linked to Indus Gene Expressions.

Premium access

Employee and EPFO history

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

Name History of Indus Gene Expressions Limited

Indus Gene Expressions has undergone 2 name changes throughout its history. The company was previously known as Indus Gene Expressions Private Limited, and Sri Balaji Biopharmaceuticals India Private Limited. The current legal name is Indus Gene Expressions Limited.

Company NameStatus
Indus Gene Expressions LimitedCurrent
Indus Gene Expressions Private LimitedPrevious
Sri Balaji Biopharmaceuticals India Private LimitedPrevious

CIN History of Indus Gene Expressions Limited

Indus Gene Expressions has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24231AP2007PLC113311, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24231AP2007PLC113311Current
U24231KA2007PLC041743Previous
U24231KA2007PTC041743Previous

Recent Activity on Indus Gene Expressions Limited

Indus Gene Expressions Limited has 19 board changes on record since 2008: 6 appointments and 13 cessations. The latest: Tanvi Sahu ceased to be Company Secretary on 31 Jan 2025.

Ceased
Tanvi Sahu ceased to be Company Secretary.
Appointed
Abhinaya Chinthamani Reddy was appointed as Additional Director.
Ceased
Vemula Nilima ceased to be Additional Director.
Appointed
Muktha Puram Krishna was appointed as Additional Director.
Ceased
Muktha Puram Krishna ceased to be Additional Director.
Ceased
Rupana Reddy Nallari ceased to be Director.
AGM
Indus Gene Expressions Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records.
Filing
Indus Gene Expressions Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Vijayawada.
Appointed
Meka Sudhakara Reddy was appointed as Additional Director.
Charges
A charge with Canara Bank amounted to Rs. 3.63 Cr with Charge ID 100369900 was registered on 04 Sep 2020.
Ceased
Prasada Reddy Kambham ceased to be Director.
Charges
A charge with Syndicate Bank amounted to Rs. 29.00 Cr with Charge ID 100313774 was registered on 21 Dec 2019.

14 earlier events are listed in the company report.

Credit Ratings, Litigation & Regulatory Alerts for Indus Gene Expressions Limited

Premium access

Credit ratings, litigation, and regulatory alerts

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Indus Gene Expressions Limited

Premium access

Corporate group structure

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

GST Compliance of Indus Gene Expressions Limited

Indus Gene Expressions has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
37AABCI9124R1ZYAndhra PradeshActive01 Jul 2017
Premium access

GST registrations and filing compliance

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Indus Gene Expressions Limited

Premium access

MCA filings and documents

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Indus Gene Expressions Limited

Indus Gene Expressions is an active public limited company based in Andhra Pradesh, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 09 February 2007 (19+ years old) and is registered under CIN U24231AP2007PLC113311.

Indus Gene Expressions reported revenue of ₹16.82 Cr for FY 2023 (up 570% YoY).

Indus Gene Expressions has 6 current directors and KMP:

Indus Gene Expressions reported a net profit of ₹10.28 Lakh (net margin 0.6%) and EBITDA of ₹11.71 Cr (EBITDA margin 69.6%) for FY 2023, as per its filed financial statements.

The compounded annual growth rate (CAGR) of the revenue of Indus Gene Expressions is 639% over five years. In the latest year (FY 2023) revenue rose 570%. CAGR is the steady yearly rate that links the first and the last year.

The GSTIN of Indus Gene Expressions is 37AABCI9124R1ZY, registered in Andhra Pradesh.

The CIN (Corporate Identification Number) of Indus Gene Expressions is U24231AP2007PLC113311. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Indus Gene Expressions has 10 court cases on record: 9 filed by the company and 1 filed against it. 3 are pending. Most are in the high courts.

Indus Gene Expressions was incorporated on 09 February 2007, making it 19+ years old. It is registered with the Registrar of Companies, Vijayawada.

Indus Gene Expressions has 24 deals on record (18 secondary share transfers, 6 funding rounds), with disclosed funding of ₹63.95 Cr; the latest was in May 2022.

The peers of Indus Gene Expressions by revenue are Cellutions Biostorage Private Limited, S4 Research Private Limited, Juniper Life Sciences Private Limited, Gangabishan Bhikulal Investment and Trading Limited, Micro Bax (India) Limited and 5 more, all in the Biotechnology industry (Biotechnology).

Tanvi Sahu ceased to be Company Secretary on 31 Jan 2025. Abhinaya Chinthamani Reddy was appointed as Additional Director on 15 Jan 2025. Vemula Nilima ceased to be Additional Director on 17 Dec 2024. Indus Gene Expressions has 19 board changes on record in total.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available